---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056882"
form_type: "8-K"
ticker: null
cik: "0001260990"
company_name: "Oncternal Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:00:14.379143+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncternal Q1 net loss $8.4M; ONCT-534 cohort fully enrolled; cash runway into Q1 2025

## Summary
- Net loss $8.4M ($2.83 per share); grant revenue $0.6M; total operating expenses $9.3M including $1.4M stock-based compensation.
- Cash, cash equivalents & short-term investments $27.0M as of March 31, 2024; no debt; projected runway into Q1 2025.
- Phase 1/2 ONCT-534 for advanced prostate cancer: fourth cohort (300 mg/day) fully enrolled; initial data expected late Q2 2024.
- Phase 1/2 ONCT-808 (ROR1 CAR T) for aggressive B-cell lymphoma open and enrolling; clinical update expected mid-2024.

## SEC filing metadata
- accession: 0000950170-24-056882
- form_type: 8-K
- cik: 0001260990
- company_name: Oncternal Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1260990/000095017024056882/0000950170-24-056882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1260990/000095017024056882/onct-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056882
- JSON: https://secwatch.observer/filing/0000950170-24-056882.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056882.txt

## Key facts
- Earnings Releases
  Oncternal Therapeutics, Inc. reported for the quarter ended March 31, 2024 results: revenue $0.6 million, net income Net loss for the first quarter was $8.4 million, or a net loss of $2.83 per share, EPS $2.83 per share, basic and diluted.
  - Period: for the quarter ended March 31, 2024
  - Revenue: $0.6 million
  - Net income: Net loss for the first quarter was $8.4 million, or a net loss of $2.83 per share
  - EPS: $2.83 per share, basic and diluted
  - Result: reported results
  source text: T cell therapy ‒ Clinical data update in mid-2024 ‒ Additional clinical data readouts in the fourth quarter of 2024 First Quarter 2024 Financial Results Our grant revenue was $0.6 million for the first quarter ended March 31, 2024. Our total operating expenses for the first quarter ended March 31, 2024 were $9.3 million, including $1.4 million in non-cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017024056882/0000950170-24-056882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.